2025 ICD-10-CM code C25.4
(Active) Effective Date: N/A Neoplasms - Malignant neoplasms of digestive organs (C15-C26) 2 Neoplasms (C00-D49) Feed
Malignant neoplasm of the endocrine pancreas. This refers to cancer of the islets of Langerhans.
Medical necessity must be established by documenting the signs, symptoms, and diagnostic findings that support the diagnosis of a malignant neoplasm of the endocrine pancreas. This documentation justifies the medical treatment rendered, such as surgery, chemotherapy, radiation therapy, and other supportive care.
The pancreas aids digestion and controls blood sugar. The endocrine pancreas (islets of Langerhans) releases hormones like insulin and glucagon. Symptoms vary depending on the hormones and resulting tumors (e.g., gastrinoma, insulinoma). General symptoms include weakness, weight loss, diarrhea, jaundice, abdominal pain, rapid heartbeat, sweating, skin rash, appetite changes, and excessive thirst or hunger. Diagnosis involves history, physical exam, blood tests (CA 19-9, blood chemistries), and imaging (CT, MRI, ERCP, TUS, EUS, PET). Treatment depends on stage and location, with surgery for resectable neoplasms, often combined with chemotherapy and radiotherapy. Advanced cases use chemotherapy and radiotherapy for palliative care.
- 2 Neoplasms (C00-D49)
- Malignant neoplasms (C00-C96)Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain specified histologies, except neuroendocrine, and of lymphoid, hematopoietic and related tissue (C00-C75)Malignant neoplasms of digestive organs (C15-C26)
In simple words: This code represents cancer of the part of the pancreas that produces hormones like insulin and glucagon, which control blood sugar.
Malignant neoplasm of the endocrine pancreas, also known as malignant neoplasm of the islets of Langerhans.The islets of Langerhans are responsible for producing hormones such as insulin, glucagon, and somatostatin. Use additional code to identify any functional activity.
Example 1: A patient presents with persistent hypoglycemia, weight loss, and tremors. Diagnostic imaging reveals a malignant tumor in the pancreas, specifically affecting the insulin-producing cells of the islets of Langerhans. C25.4 is used to code the malignant neoplasm of the endocrine pancreas (insulinoma)., A patient experiences severe peptic ulcers, diarrhea, and abdominal pain.Elevated gastrin levels are detected, and a malignant gastrinoma is located in the pancreas during an endoscopic ultrasound. C25.4 is applied to code this endocrine pancreas malignancy., During a routine abdominal CT scan for unrelated reasons, a small, well-defined tumor is discovered in the tail of the pancreas.A biopsy confirms a malignant glucagonoma, a tumor of the endocrine pancreas. C25.4 accurately reflects the diagnosis.
Documentation should include details of the history, physical examination findings, laboratory results (including blood chemistries and tumor markers), imaging studies (CT, MRI, ERCP, TUS, EUS, PET), biopsy results confirming malignancy, and the specific type of endocrine tumor (e.g., insulinoma, gastrinoma, glucagonoma).
- Specialties:Oncology, Endocrinology, Gastroenterology, General Surgery
- Place of Service:Inpatient Hospital, On Campus-Outpatient Hospital, Physician Office